Hexons from adenovirus serotypes 5 and 48 differentially protect adenovirus vectors from neutralization by mouse and human serum

• Andrew W. Harmon,

  Roles Conceptualization, Formal analysis, Investigation, Writing – original draft, Writing – review & editing

  Affiliation Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Rituparna Moitra,

  Roles Resources

  Affiliation Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Zhili Xu,

  Roles Investigation, Writing – review & editing

  Affiliation Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  ⨯
• Andrew P. Byrnes

  Roles Conceptualization, Formal analysis, Funding acquisition, Supervision, Writing – original draft, Writing – review & editing

  * E-mail: Andrew.Byrnes@fda.hhs.gov

  Affiliation Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America

  http://orcid.org/0000-0003-1135-2629

  ⨯